Cancel
Paratek Pharmaceuticals
See Linkedin
Paratek Pharmaceuticals Employees
13 people indexed:
-
Adam Woodrow
President and Chief Commercial Officer
l567.xy4yujf@vsl91u5ybgfnl.yxq Sign up to see emailbzs7.3y4isb2@7vg1iy6n64xun.5uf Sign up to see email -
4qngz.70dj0@zgwwwzg9fd01q.wv8 Sign up to see email
-
i245.nn8yl5j@9n28jgjqj5vn4.y3i Sign up to see email
-
xxv0l.6j30zn7@x592xwngwxfx4.8gf Sign up to see email
-
dz6f.g9i@j0ssw9gi5g139.0ux Sign up to see email
-
Jonathan Light
General Counsel, Corporate Secretary and Chief Compliance Officer
9d14wwy3.9v079@uduvvw154f0fs.wzv Sign up to see emailfq2uz5y0.fub6x@u099xy8bb5822.w6w Sign up to see email -
2fyiq.w5w4fv1@35s76vzj2s8uq.9bj Sign up to see email
-
Katie Zitoli
Senior Director, Finance and Controller
n8jy1.dfvb3j@w231s8bq754u6.343 Sign up to see emailjb878.x6dg75@jf5d5wu792sx1.22n Sign up to see email -
Kelly Wright
Senior Director, Medical Publications
s68q9.62f0f9@bb82f93s1q9nu.5q3 Sign up to see email4uv90.jfsfds@vbxf0x331f0zu.sn6 Sign up to see email -
Lauren Stanton
Director, Human Resources and Talent Acquisition
1j82w0.yx2f8wq@3qwwzd3v72g25.fqx Sign up to see email9ygi8j.iyqzqf4@23889qyjddi07.vb2 Sign up to see email -
Lindsay Moss
Associate Director, Contracts Development and Management
5wxj864.v8xj@wx6buxu1v8xj7.gff Sign up to see emailf75gugw.wu25@522b1wv0u7wqf.1xv Sign up to see email -
Randy Brenner
Chief Development and Regulatory Officer
fg4jq.10fu688@gjs98ilqui08z.9g5 Sign up to see email2fi4u.6z888j4@fiv0l7sufvjg0.jf7 Sign up to see email -
Stephen Viccica
Senior Director, Regulatory Affairs
13401zy.1l4uz8z@d0w7w1w710flx.wyu Sign up to see email4gujuqy.u5wq3wq@l36lyl588g9l7.l90 Sign up to see email
Paratek Pharmaceuticals' Solutions
Paratek Pharmaceuticals focuses on developing transformative solutions for patients facing infectious diseases and other challenging medical conditions. One of their standout products is NUZYRA, an FDA-approved antibiotic within the tetracycline class. NUZYRA is specifically designed for treating community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. This product underscores Paratek's commitment to addressing the critical issue of antimicrobial resistance, which poses a significant threat to global public health.
Paratek Pharmaceuticals' Locations
Paratek Pharmaceuticals operates from two major offices located in King of Prussia, Pennsylvania, and Boston, Massachusetts. These strategic locations enable the company to leverage the rich biopharmaceutical research and development ecosystems present in both regions. Having offices in these key areas allows Paratek to collaborate closely with academic institutions, healthcare providers, and other industry stakeholders, thereby enhancing their ability to innovate and bring new therapeutic solutions to market.
Paratek Pharmaceuticals' Compliance Programs
Paratek Pharmaceuticals is deeply committed to maintaining ethical business practices and ensuring compliance with applicable laws, regulations, guidelines, and policies. The company's comprehensive compliance programs reflect this dedication, establishing a robust framework for ethical conduct across all operations. These programs are designed to foster a culture of integrity and accountability, ensuring that all employees adhere to the highest standards of professional behavior. This commitment to ethics and compliance not only protects the company but also builds trust with patients, healthcare providers, and regulatory bodies.
Paratek Pharmaceuticals' Collaboration and Rights
Paratek Pharmaceuticals holds the worldwide rights to omadacycline, a significant asset in their portfolio. The company has also forged a key collaboration for the development and commercialization of omadacycline in the Greater China region. This strategic partnership expands Paratek's global reach and leverages local expertise to enhance the drug's availability and impact. By maintaining global rights and fostering international collaborations, Paratek ensures that their innovative treatments can benefit a wider patient population.
Paratek Pharmaceuticals' FDA Approvals
In addition to NUZYRA, Paratek Pharmaceuticals has achieved FDA approval for SEYSARA, a treatment for the inflammatory lesions associated with non-nodular moderate to severe acne vulgaris in patients aged 9 years and older. This approval highlights the company's capability to secure regulatory endorsements for their medications, underscoring their expertise in developing effective treatments for dermatological conditions. By expanding their product portfolio with FDA-approved solutions, Paratek reinforces their commitment to addressing unmet medical needs across various therapeutic areas.
Report inaccurate information
Report inaccurate information
